Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Life Science Reit Plc ( (GB:LABS) ) just unveiled an announcement.
Life Science REIT reported that the value of its property portfolio fell 7.8% to £332.6 million as at 31 December 2025, while its unaudited EPRA net tangible assets declined 13% to £201.8 million, or 57.7 pence per share, reflecting weaker market valuations and higher leverage to fund ongoing development projects. The decline was driven mainly by outward yield shifts across the portfolio, exacerbated by softening laboratory demand caused by reduced venture capital and second-stage funding for life science companies, with the Cambourne Park Science and Technology Campus seeing the sharpest hit as persistent vacancies and capex needs led valuers to treat it as an office/business park rather than a prime life science asset; elsewhere, modest value declines were partly offset by improving demand and rising ERVs at Oxford Technology Park and a supportive lease regear at Herbrand Street in Bloomsbury, ahead of full-year results due in April 2026.
The most recent analyst rating on (GB:LABS) stock is a Hold with a £38.00 price target. To see the full list of analyst forecasts on Life Science Reit Plc stock, see the GB:LABS Stock Forecast page.
Spark’s Take on GB:LABS Stock
According to Spark, TipRanks’ AI Analyst, GB:LABS is a Neutral.
The overall stock score is primarily driven by significant financial instability and negative corporate events. The managed wind-down proposal and asset liquidation plan are major concerns, overshadowing any short-term technical strengths. The lack of profitability and negative valuation metrics further contribute to a low score.
To see Spark’s full report on GB:LABS stock, click here.
More about Life Science Reit Plc
Life Science REIT plc is a UK-listed real estate investment trust focused on owning and developing life science and technology properties, with a portfolio concentrated in key innovation hubs such as the UK’s “Golden Triangle” markets and assets including science and technology campuses and laboratory-led business parks.
Average Trading Volume: 604,429
Technical Sentiment Signal: Sell
Current Market Cap: £137.9M
See more insights into LABS stock on TipRanks’ Stock Analysis page.